http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-422916-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b057fddee6645785fc5df7006be3bb3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-45 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0626 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0621 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-36 |
| filingDate | 2017-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78c94fd9ee98b24c3d598afbaee53c19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00e91a01a74c9b61a38b999e9776416b |
| publicationDate | 2019-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PL-422916-A1 |
| titleOfInvention | A method for obtaining pigmented cells in vitro by differentiating human induced pluripotent stem cells |
| abstract | The subject of the application is a method for obtaining pigmented cells in vitro by differentiating human induced pluripotent stem cells, characterized in that it includes the following steps: Y27632 inhibitor, preferably at a density of 2-2.5 x 104 cells / cm2, and then cultured, preferably for 4 days, to form EB embryoid bodies, b) obtained in step a) EB embryoid bodies are collected and seeded, preferably on an adherent dish, and culture in iMEF cell medium is carried out, preferably for 18 hours, selection of progenitors in N1 medium containing: N2 supplement, preferably in a single dilution, fibronectin, preferably at a concentration of 250 ng / ml, a solution of antibiotics containing penicillin and streptomycin P / S, preferably at a concentration of 1 00 U / ml / 100 µg / ml, dissolved in DMEM / F12 medium, preferably for 10 days, periodically removing dead cells and supplementing the nutrient components, d) the obtained progenitor cells are dissociated, seeded, preferably at a density of 0.5 - 2 x 105 / cm2, on plates covered with laminin and poly-ornithine and their expansion is carried out, preferably for 7 days, in N2 medium containing: N2 supplement, preferably in a single dilution, laminin, preferably at a concentration of 1 mg / ml, preferably bFGF at a concentration of 20 µg / ml, FGF8, preferably at a concentration of 100 ng / ml, P / S, preferably at a concentration of 100 U / ml / 100 µg / ml, dissolved in DMEM / F12 medium, and the cells obtained before their use in the next stage optionally stored frozen in N2 medium with 10% DMSO at a density of 2 million cells / ml, e) carried out, preferably for 7-16 days, final differentiation of the cells by culturing them in N3 medium containing: N2 supplement, preferably once dilution, laminin, preferably at a concentration of 1 mg / ml, dibutyryl-cAMP, preferably at a concentration of 0.5 mM, ascorbic acid, preferably at a concentration of 200 μM, P / S, preferably at a concentration of 100 U / ml / 100 μg / ml, dissolved in DMEM / F12 medium, resulting in melanin-pigmented human cells. The application also includes the use of cells obtained in the above method. |
| priorityDate | 2017-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.